Asset Details
Do you wish to reserve the book?
Identification of neutral tumor evolution across cancer types
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identification of neutral tumor evolution across cancer types
Do you wish to request the book?
Identification of neutral tumor evolution across cancer types
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Identification of neutral tumor evolution across cancer types
2016
Overview
Andrea Sottoriva, Trevor Graham and colleagues analyze tumor sequencing data and show that a substantial proportion of cancers of many different types are characterized by neutral evolution resulting in a characteristic power-law distribution of the mutant allele frequencies. This neutral framework provides a new way to interpret cancer genomic data and to discriminate between functional and non-functional intratumoral heterogeneity.
Despite extraordinary efforts to profile cancer genomes, interpreting the vast amount of genomic data in the light of cancer evolution remains challenging. Here we demonstrate that neutral tumor evolution results in a power-law distribution of the mutant allele frequencies reported by next-generation sequencing of tumor bulk samples. We find that the neutral power law fits with high precision 323 of 904 cancers from 14 types and from different cohorts. In malignancies identified as evolving neutrally, all clonal selection seemingly occurred before the onset of cancer growth and not in later-arising subclones, resulting in numerous passenger mutations that are responsible for intratumoral heterogeneity. Reanalyzing cancer sequencing data within the neutral framework allowed the measurement, in each patient, of both the
in vivo
mutation rate and the order and timing of mutations. This result provides a new way to interpret existing cancer genomic data and to discriminate between functional and non-functional intratumoral heterogeneity.
